PB-223-MMAE ADC / Precision Biologics - LARVOL DELTA

Precision Biologics' New PB-223 ADC Targeting Multiple Cancer Types to Be Highlighted in Keynote at 6th ACE Drug Discovery Summit (PRNewswire) - "Precision Biologics, Inc. CEO Philip M. Arlen, MD gives a Keynote presentation describing in vitro and in vivo efficacy of its novel tumor-specific antibody-drug-conjugate PB-223 ADC (PB-vcMMAE-5). Recent tumor killing data showing specific non-toxic anti-tumor activity in several human cancer types expressing truncated core 2 O-glycans will be reported in 'PB-223, A Novel Antibody Drug Conjugate Targeting Truncated Core-2 glycans in Solid Tumors'..."

Preclinical • Solid Tumor

Precision Biologics, Inc. reports that in vitro and in vivo efficacy of the novel ADC, using its anti-core 2 O-glycans anti-human carcinoma mAb PB-223 (PB-vcMMAE-5), against human ovarian cancer expressing truncated core 2 O-glycans will be presented in a poster at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Ovarian Cancer Research (PRNewswire) - "Data presented in this study show that PB-vcMMAE-5 at 1 mg/kg did not significantly reduce tumor volume compared with PBS, whereas PB-vcMMAE-5 at 6 and 9 mg/kg induced robust reduction of tumor volume."

Preclinical • Ovarian Cancer